Clinical Trials on De Novo Myelodysplastic Syndromes

Total 2308 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Belinostat in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Aplastic Anemia | de Novo Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

Canada, United States
Fred Hutchinson Cancer Center

Completed

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
University Children's Hospital Basel
Swiss National Science Foundation; Fondation Botnar

Completed

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis (D2OBREATH)

De Novo Lipogenesis (DNL)

Switzerland
Novartis

Completed

Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation

de Novo Liver Transplantation

Germany, Italy, Switzerland
University Hospital, Tours
Astellas Pharma Inc

Unknown

Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) (ADEQUATE)

De Novo Transplant Disease

France
University of Chicago
National Cancer Institute (NCI)

Completed

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

De Novo Kidney Transplant Recipients
Rigshospitalet, Denmark

Completed

Early Detection of de Novo Cancer in Liver Transplant Recipients (DETECT)

Liver Transplant Disorder | De Novo Cancer
Novartis Pharmaceuticals

Completed

Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients

De Novo Renal Transplantation

Norway
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

De Novo Kidney Transplantation

Belgium, France, Netherlands, Spain, Sweden, Austria, Italy, Germany, United Kingdom, Hungary, Poland, Czech Republic
Novartis

Completed

Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients

De Novo Kidney Transplantation
City of Hope Medical Center

Completed

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndromes

United States
Astellas Pharma Inc

Completed

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

De Novo Kidney Transplant Patients

China
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects (Maple)

de Novo Liver Transplant Subjects

Korea, Republic of
Erasmus Medical Center
Hoffmann-La Roche

Completed

Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation

De Novo Renal Transplant Recipient.

France, Spain, Taiwan, Denmark, Australia, United Kingdom, Germany, Canada, Belgium, China, Sweden, Netherlands, Austria, Brazil, Estonia, Lithuania, Norway, Poland, Venezuela
Medinol Ltd.

Completed

NIRTRAKS Post-Market Study (NIRTRAKS) (NIRTRAKS)

de Novo Stenotic Lesions in Native Coronary Arteries

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditions

United States
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
Institut Curie
National Cancer Institute, France; Fondation ARC

Terminated

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)

Acute Myeloid Leukemia, in Relapse | Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome | de Novo Acute Myeloid Leukemia at Diagnostic

France
Biotronik AG

Completed

First in Man Trial - BIOSOLVE-I (BIOSOLVE-I)

de Novo Lesions in Native Coronary Arteries

Netherlands, Switzerland, Germany, Belgium
University of Washington
National Cancer Institute (NCI); Bayer

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Aflibercept in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | de Novo Myelodysplastic Syndromes

United States
Biotronik AG

Completed

Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice (ENERGY)

De Novo and Re-stenosed Coronary Artery Lesions

Switzerland, Netherlands, Israel, Spain, Latvia, Germany, Austria, Belgium, France, Ireland
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Kidney de Novo Transplant
Novartis

Completed

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (EVIDENCE)

Renal Transplantation | de Novo Kidney Transplant Recipients

Italy
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...

United States
National Cancer Institute (NCI)

Completed

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
University Hospital, Tours
Astellas Pharma Inc

Unknown

Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) (ADEQUATEartère)

De Novo Transplant Disease

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Previously Treated Myelodysplastic Syndrome | Fanconi Anemia | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia in Remission

United States, Brazil
Boston Scientific Corporation

Completed

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program (ARRIVE 2)

Cardiovascular Disease | de Novo Coronary Lesions

United States
Case Comprehensive Cancer Center

Completed

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia... and other conditions

United States
Astellas Pharma Korea, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation (AdProCISE)

de Novo Kidney Transplantation

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
Shenzhen People's Hospital

Not yet recruiting

Resting Full-cycle Ratio-guided Step by Step Balloon Dilation (REDUCE)

de Novo Coronary Lesions
Novartis Pharmaceuticals

Completed

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

de Novo Heart Failure

United States
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...

Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Kidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies Development

United States
Novartis Pharmaceuticals

Completed

Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients (Spartacus)

Pharmacokinetics Study in de Novo Kidney Transplantation

Germany
Abbott Medical Devices
Baim Institute for Clinical Research

Withdrawn

Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery (I-WIN)

With de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Bail-Out Stenting and Target-vessel Failure After Drug Coated Balloon Coronary percutaneouS Angioplasty for de Novo Lesions (BOSS)

PCI | De Novo Stenosis | DCB

Italy
China National Center for Cardiovascular Diseases

Recruiting

STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (STENTLESS)

De Novo Stenosis | Drug-coated Balloon | Drug-eluting Stent

China
Medinol Ltd.

Completed

MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR)

de Novo or Restenosis Lesions

Japan
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Juvenile Myelomonocytic Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Childhood Myelodysplastic Syndromes | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States

Clinical Trials on De Novo Myelodysplastic Syndromes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations